How to Use Benzodiazepine Refills to Reassess PTSD Risk
How should clinicians use posttrauma benzodiazepine refill behavior to identify patients who need reassessment for PTSD and unresolved distress?
Some patients continue seeking benzodiazepines after the immediate posttrauma period, and that pattern may carry more clinical meaning than the first prescription fill. This guide applies to patients who already filled a new benzodiazepine prescription after trauma and helps clinicians interpret refill behavior as a marker for reassessment.
-
Separate one-time users from persistent users
Among patients who filled at least one posttrauma benzodiazepine prescription, classify them by whether they had any additional dispensing within the initial supply duration plus 7 days. The study defined persistent users as those with 1 or more refills in that window and discontinued users as those without an additional dispensing.
-
Treat refill requests as the key risk signal
Use refill behavior, not initial purchase timing, as the main trigger for concern about subsequent PTSD risk. In the 5-group analysis, 12-month PTSD risk was 9.1% in early-persistent users and 9.9% in late-persistent users, compared with 4.1% in early-discontinuation users, 4.4% in late-discontinuation users, and 5.2% in nonpurchasers.
-
Recognize that discontinuation resembles nonpurchase
If the patient does not obtain an additional dispensing within the study's refill window, interpret that pattern as time-limited use rather than a clear excess-risk signal. In the fully adjusted model, neither early-discontinuation nor late-discontinuation differed significantly from nonpurchase, with hazard ratios of 0.88 and 0.99.
-
Prioritize active reassessment in persistent users
If the patient obtains a refill, actively reassess because the study found significantly elevated PTSD risk in both persistent groups. Compared with nonpurchasers, fully adjusted hazard ratios were 1.60 for early-persistent users and 2.07 for late-persistent users.
-
Interpret persistence as unresolved clinical need, not proven causation
Use ongoing benzodiazepine use as a marker that acute distress may not have resolved and that additional intervention may be needed. The authors state that the elevated risk in persistent users could reflect unresolved underlying symptom severity, more intensive concurrent treatment needs, or a medication-related effect, so persistence should prompt reassessment rather than a simple causal conclusion.
Clinical Considerations
- Residual confounding is especially important in the persistence analysis, because refill behavior may reflect greater underlying symptom severity.
- The study cannot determine whether higher PTSD incidence in persistent users was caused by the medication or by unresolved psychiatric burden.
- Concurrent mental health treatment was only partially examined and could differ across groups.
- Exposure timing was measured in days, limiting assessment of ultra-acute effects within the first 48 to 72 hours.
Bottom Line
After trauma, a benzodiazepine refill request should be treated as a high-priority reassessment point because persistent use, not the initial short-term fill, was the clearest marker of elevated subsequent PTSD risk.
